Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion type Assertion NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_head.
- NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion description "[Immunohistochemistry results indicated that Id2 was expressed strongly in 21 of 27 (78%) ALCL tumors (79% anaplastic lymphoma kinase [ALK]-negative and 75% ALK-positive), in 5 of 10 (50%) extranodal natural killer/T (NK/T)-cell lymphomas of the nasal type, in 2 of 8 (25%) cutaneous ALCLs, in 2 of 9 (22%) enteropathy type T-cell lymphomas, in 1 of 5 (20%) peripheral T-cell lymphomas not otherwise specified, and in 1 of 8 (13%) T-cell prolymphocytic leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_provenance.
- NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion evidence source_evidence_literature NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_provenance.
- NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion SIO_000772 18085637 NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_provenance.
- NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion wasDerivedFrom befree-2016 NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_provenance.
- NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_assertion wasGeneratedBy ECO_0000203 NP645637.RAl4GEp16D1JmI5OY_oiKz9ea58L_1tEe0WVuvKoMAicM130_provenance.